Cargando…
Mechanism of Abnormal Coagulation Induced by Tigecycline in Cancer Patients
Tigecycline is a broad-spectrum active intravenous antibiotic that is active against methicillin-resistant staphylococcus aureus. In Phase 3 and 4 clinical trials, increased all-cause mortality was observed in patients treated with tigecycline compared to patients in the control group. The reason fo...
Autores principales: | Sun, Li-Hua, Bai, Kun-Hao, Wu, Guo-Yan, Tian, Xiao-Peng, Zou, Zhi-Qing, Wang, Da-Wei, Dai, Yu-Jun, Chen, Si-Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294380/ https://www.ncbi.nlm.nih.gov/pubmed/35865948 http://dx.doi.org/10.3389/fphar.2022.891952 |
Ejemplares similares
-
Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies
por: Zhang, Lei, et al.
Publicado: (2023) -
Population pharmacokinetics of tigecycline in critically ill patients
por: Luo, Xiangru, et al.
Publicado: (2023) -
The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties
por: Xu, Zhijie, et al.
Publicado: (2016) -
Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock
por: Borsuk-De Moor, Agnieszka, et al.
Publicado: (2018) -
Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: A multicenter retrospective study in China
por: Leng, Bing, et al.
Publicado: (2022)